Amyloid-ß immunotherapy for alzheimer disease: Is it now a long shot?
Ann Neurol
; 85(3): 303-315, 2019 03.
Article
em En
| MEDLINE
| ID: mdl-30635926
ABSTRACT
The amyloid-ß (Aß) cascade hypothesis of Alzheimer disease (AD) holds that brain accumulation of Aß initiates the disease process. Accordingly, drug research has targeted Aß production, clearance, and deposition as therapeutic strategies. Unfortunately, candidate drugs have failed to show clinical benefit in established, early, or prodromal disease, or in those with high AD risk. Currently, monoclonal antibodies specifically directed against the most neurotoxic Aß forms are undergoing large-scale trials to confirm initially encouraging results. However, recent findings on the normal physiology of Aß suggest that accumulation may be compensatory rather than the pathological initiator. If this is true, alternative strategies will be needed to defeat this devastating disease. ANN NEUROL 2019;85303-315.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Encéfalo
/
Peptídeos beta-Amiloides
/
Doença de Alzheimer
/
Anticorpos Monoclonais
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article